In the drinking-water medication line, Shizhi Powder veterinary-grade API is formulated into water-soluble powders and granules for poultry and swine operations where mass administration through nipple or bell drinkers is the primary route. Because supplier assay and particle-size specifications for Shizhi Powder vary by manufacturer, the ranges below are standard industrial design envelopes derived from veterinary API powders of similar potency and route requirements. The powder is dry-blended with dextrose monohydrate or lactose monohydrate as a carrier, anhydrous citric acid or a phosphate buffer for pH stabilization, and polyvinylpyrrolidone or silica as an anti-caking and dispersion aid. Inclusion of Shizhi Powder is fixed by the target drinking-water concentration, typically within 0.5–1.0 g active substance per liter of finished drinking water; in the dry powder this corresponds to an API addition ratio of 2.5–20.0% w/w depending on the approved species-specific dose, withdrawal period constraints, and diurnal water intake variability. Dissolution is verified by adding a 1.0% w/v solution to water at 25°C and measuring residue on a 45 µm sieve after 5 min of stirring; targets are set at a maximum of 0.5% insoluble residue according to the wet sieve procedure of Ph. Eur. 2.9.12. Compliance for such products is governed by 21 CFR Part 520, Directive 2001/82/EC, and stability evaluation under VICH GL2, with finished product moisture content maintained at or below 5.0% w/w to prevent caking during warehouse storage.

Production-scale processing of water-soluble granules begins with a pre-mix of Shizhi Powder and a hydrophilic carrier in a 500 L ribbon blender operating at 20–25 rpm for 15–20 min; the blend is then transferred to a fluid-bed granulator when granule form is specified, using purified water or an aqueous binder solution sprayed at 50–65°C inlet air temperature and product temperature not exceeding 40°C. Batch-to-batch variance in a high-humidity production environment above 60% RH is controlled by closed material handling and pre-conditioning of the carrier; failure to control moisture leads to clumping in the granulator filter bags and irregular particle-size distribution. Granulated material is milled through a 0.8–1.0 mm screen and screened to retain particles between 150 µm and 850 µm. Terminal finished products include single-dose sachets, multi-kilogram bulk packs for proportioning pumps, and granular formulations for direct addition to header tanks.

What Limits Homogeneity in Medicated Premix Lines and How Is Shizhi Powder Diluted?

Medicated premix production uses Shizhi Powder as a low-inclusion active component diluted on a solid carrier such as calcium carbonate, corn cob meal, or rice hulls. The addition ratio is derived from the target complete feed concentration and the intended mixing rate: the API is typically first blended at 5.0–50.0 g active/kg premix, equivalent to 0.5–5.0% w/w of active substance in the premix, and the premix is then metered into final feed at 1.0–5.0 kg per tonne. When the required final feed dose is below 1.0 ppm, two-stage dilution is mandatory because single-stage blending in a 500 kg horizontal paddle mixer cannot reliably achieve a coefficient of variation below 10.0%. The carrier is selected for bulk density within 0.55–0.75 g/cm³ and moisture content below 10.0% w/w; hygroscopic carriers increase the risk of segregation and microbial growth. Compliance is anchored to FAMI-QS Code, GMP+ BA1, Regulation (EC) No 183/2005, Regulation (EU) 2019/4, and 21 CFR Part 225 for medicated feed mills.

Production flow involves a pre-mix stage: Shizhi Powder is combined with an equal mass of carrier in a 50 kg drum mixer for 10 min, then added to the main batch and mixed for 15–20 min in a double-shaft paddle mixer operating at blade tip speeds below 1.5 m/s. Over-mixing beyond 30 min leads to electrostatic charge generation and segregation of the active fraction, especially at API particle sizes below 50 µm; anti-static liquid food-grade oil is sprayed at 0.1–0.3% w/w only when dust control is critical. Terminal finished product types include 25 kg paper bags of premix, medicated loose meals, pelleted complete feed, and top-dress powders for dairy cattle. Equipment release testing follows recovery verification with residue limits not exceeding 10 ppm of carryover into subsequent non-medicated batches.

Oral tablet manufacture from Shizhi Powder veterinary-grade API is configured around the powder’s particle-size distribution, bulk density, and compressibility; direct compression is reserved for low-dose formulations where the API content is below 10.0% w/w and the excipient matrix can absorb the physical variability of the active. Wet granulation is the preferred route when the API inclusion is between 15.0% w/w and 50.0% w/w of the core tablet weight. The blend consists of microcrystalline cellulose, pregelatinized starch, crospovidone as disintegrant at 2.0–4.0% w/w, and magnesium stearate at 0.25–0.50% w/w. Granulation is carried out in a high-shear mixer with purified water or a 5.0% w/v polyvinylpyrrolidone binder solution; the wet mass is dried in a fluid-bed dryer to a loss on drying of 1.0–2.5% w/w, then milled through a 1.0 mm screen. Compression is performed on a rotary tablet press with 10 mm round tooling at 8–20 kN compression force, targeting tablet hardness of 40–70 N and friability below 1.0% per USP <1216>.

Quality release tests follow USP <905> or Ph. Eur. 2.9.40 for uniformity of dosage units with an acceptance value not exceeding 15.0, disintegration per USP <701> with a limit of 30 min in water at 37°C, and dissolution per USP <711> using the species-relevant medium. Film-coated tablets use an aqueous ethylcellulose or hydroxypropyl methylcellulose coating applied in a side-vented coating pan, with weight gain controlled at 2.0–3.5% w/w. Operational boundaries include avoiding wet granulation when the active moiety is moisture-sensitive; in that case a dry-granulated slugging or roller compaction line is substituted. Finished dosage types include scored tablets for small-animal dose adjustment, chewable tablets with palatability enhancers, and coated matrix tablets for sustained release in companion animals.

Sterile Injectable Freeze-Drying and Terminal Sterilization Parameters

Parenteral grade applications for Shizhi Powder require the API to be dissolved or suspended in Water for Injection under ISO 14644-1 class 5 conditions. The formulation addition ratio for injectable solutions is controlled between 1.0% w/v and 20.0% w/v depending on aqueous solubility and intended dose volume; suspensions may exceed 20.0% w/v only when viscosity and syringeability are confirmed by plunger-force testing on 18 G needles. Isotonicity is adjusted with sodium chloride or mannitol to 280–310 mOsm/kg, and pH is buffered between 6.0 and 7.5 for intramuscular or subcutaneous administration. Sterilization strategy is selected after thermal stress testing: if the active substance retains assay above 95.0% following a 121°C moist-heat cycle of 15 min, terminal sterilization is preferred; if not, aseptic filtration through a 0.22 µm polyvinylidene fluoride membrane is mandated. Production experience with 100 mL vial lines shows that terminal sterilization at 121°C can increase visible particulate levels if the formulation contains uncomplexed buffering salts, which must be pre-filtered through 0.45 µm membranes.

The downstream process for injectable solutions uses a closed jacketed stainless-steel mixing vessel with bottom-mounted magnetic agitation; compounding is followed by pH and osmolality adjustment, then sterile filtration with two 0.22 µm filters in series. The filtered bulk is held no more than 8 h before filling to control bioburden, and filling is performed in a restricted access barrier system with peristaltic pump dosing to 20 mL, 50 mL, and 100 mL Type I glass vials. Lyophilized injectables require an additional shelf-freeze cycle with a primary drying temperature of -25°C to -10°C and chamber pressure of 0.2–0.4 mbar, followed by secondary drying at 25°C to achieve residual moisture below 2.0% w/w. Cleanroom monitoring follows EU GMP Annex 1 and 21 CFR 210/211, with viable air limits not exceeding 1 CFU/m³ in grade A zones and non-viable particles ≥0.5 µm not exceeding 3,520 particles/m³. Terminal finished product types include single-dose vials, multidose vials with preservative such as 0.9% w/v benzyl alcohol, and lyophilized cakes for reconstitution.

Release testing for sterile injectables is carried out against a matrix of methods and numerical acceptance limits:

Oral solution and drench manufacturing applies Shizhi Powder to liquid vehicles where dose titration, rapid absorption, and flexible administration to swine, cattle, and sheep are more important than physical stability of a solid matrix. The API is incorporated at 5.0–25.0% w/v for high-dose drench products and at 1.0–5.0% w/v for low-dose oral solutions administered through a dosing gun or automatic dispenser. The vehicle is typically purified water blended with propylene glycol or glycerol at 10.0–30.0% v/v to enhance solubility and suppress crystallization; sodium benzoate at 0.1–0.2% w/v or potassium sorbate at 0.1% w/v is used for antimicrobial preservation in multidose packs. Final pH is adjusted to 4.5–6.0 with citric acid or disodium phosphate, with viscosity maintained below 100 mPa·s at 25°C to ensure reproducible draw into a 20 mL drench gun. Compliance is set by 21 CFR Part 520, Directive 2001/82/EC, and stability testing under VICH GL2; fill volume and pH drift are monitored over 24 months.

On the manufacturing floor, the liquid is compounded in a 500 L jacketed stainless-steel vessel with a high-shear rotor-stator mixer operating at 3,000 rpm until the API passes a 45 µm in-line filter, then the bulk is recirculated through a 5 µm bag filter to remove undissolved particles. Batch-to-batch variance in low-pH vehicles is controlled by pre-dissolving Shizhi Powder in a cosolvent premix before aqueous dilution; direct addition to cold water below 15°C can produce slow dissolution and temporary cloudiness that clogs filling nozzles. Filling is performed on a volumetric piston line into amber polyethylene terephthalate or high-density polyethylene bottles with induction-sealed closures. Terminal finished product types include companion-animal oral syrups, cattle drench packs with applicator caps, sheep oral dosing bottles, and mixing jugs for proportioner systems in poultry houses.

When Shizhi Powder Is Dispersed in Hard Capsule Powder Blends for Companion Animals

Hard capsule dosage forms are selected when the API is intended for companion animals and dose flexibility is achieved by capsule count rather than tablet splitting. Shizhi Powder is dry-blended with lactose monohydrate or microcrystalline cellulose and a flow aid such as colloidal silicon dioxide at 0.1–0.5% w/w; the API addition ratio is typically 5.0–40.0% w/w of the powder fill weight. The blended material is filled into size 0 or size 1 hard gelatin or hydroxypropyl methylcellulose capsules using a dosator or tamping-pin capsule filling machine operating at 30,000–70,000 capsules/h. Weight variation is controlled to ±5.0% for fill weights above 300 mg and ±7.5% for fill weights below 300 mg per USP <905>, with dissolution acceptance per USP <711> in 900 mL of 0.1 M hydrochloric acid at 37°C using a paddle apparatus at 50 rpm. Regulatory compliance is framed by 21 CFR 211 and Directive 2001/82/EC for finished veterinary medicines.

Process limits for hard capsule production include maintaining the powder blend at or below 45% RH and 25°C because higher humidity can soften gelatin shells and cause telescoping or sticking during filling. HPMC capsule shells are specified when the target market requires vegetarian labeling or when fill material contains hygroscopic carriers; shell brittleness below 35% RH is a known failure mode in capsule printing and banding. Equipment cleaning between batches uses vacuum extraction and alcohol-wetted lint-free wipes to keep carryover below 10 ppm, and the fill head is lubricated with food-grade oil only at intervals specified by the machine builder to prevent oil migration into the powder. Terminal finished product types include tamper-evident blister packs, high-density polyethylene bottles with silica desiccant canisters, and veterinary dispensing bottles for single-owner prescriptions.